PubMed · 8023217
Hydroxyurea-induced acute interstitial lung disease.
Abstract
Hydroxyurea is a cytotoxic agent that is being increasingly used for a number of malignant and nonmalignant systemic diseases. This agent is particularly well tolerated, with dose-related myelosuppression being the primary side effect. We describe a patient who had patchy interstitial infiltrates with cavitation 2 months after the start of therapy with hydroxyurea. After hydroxyurea therapy was discontinued and empiric corticosteroid therapy was given, the pulmonary infiltrates resolved. This is a case of presumed hydroxyurea-induced lung disease, the first with supportive lung biopsy material. It is essential for physicians to be aware of this potentially life-threatening toxicity.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
M S Kavuru, T Gadsden, A Lichtin, G Gephardt. 1994. Hydroxyurea-induced acute interstitial lung disease.. https://doi.org/10.1097/00007611-199407000-00022
Cite the original work for its findings. Save a collection to share your selection of sources.